# Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

> **NCT05166889** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1132 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Tozorakimab
- **DRUG:** Tozorakimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05166889
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-03
- **Primary completion:** 2026-01-19
- **Final completion:** 2026-03-11
- **Target enrollment:** 1132 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166889, "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05166889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*